Latest Regulatory Approval News

Argosy Minerals has made significant strides in developing its Rincon Lithium Project in Argentina, securing a 40MW energy infrastructure agreement and completing a $2 million placement to fund ongoing feasibility and engineering works.

Zeus Resources has completed the acquisition of the Casablanca Antimony Project in Morocco, confirming exceptional antimony grades, while divesting its Mortimer Hills lithium project with a structured royalty deal.

Vonex Limited has taken a key step in its acquisition by Maxo Telecommunications, lodging a draft Scheme Booklet with ASIC that includes an independent expert’s report. This move brings the proposed takeover closer to shareholder approval and regulatory clearance.

Bindi Metals reports steady progress on its Lisa antimony-gold project in Serbia alongside promising gallium mineralisation at its Australian Biloela copper-gold project, maintaining a solid cash position.

Genesis Resources has completed its acquisition of full ownership of the Plavica project in North Macedonia and is advancing environmental studies while preparing for drilling campaigns in Australia’s Northern Territory.

Audalia Resources has completed critical drilling programs at its Medcalf vanadium-titanium-iron project, progressing resource upgrades and mine design while managing tight cash reserves and financing arrangements.

Nova Eye Medical has reported a record A$29.2 million revenue for FY25, driven by strong sales growth and improved profitability in its glaucoma segment. The company targets breakeven EBITDA in the first half of FY26 alongside continued cash flow improvements.

Manuka Resources has declared a maiden Probable Ore Reserve of 39,000 ounces of gold at its historic Mt Boppy Open Pit, underpinning a cutback project that adds significant value to its Cobar Basin production plan.

VHM Limited has secured a crucial mining licence for its Goschen Rare Earths and Mineral Sands Project, alongside key domestic and international partnerships and a successful $8.6 million capital raise.

Paradigm Biopharmaceuticals has advanced its global Phase 3 trial for knee osteoarthritis pain with active patient recruitment in Australia and the US, backed by a $41.2 million convertible note facility. The company also expanded its osteoarthritis portfolio through the acquisition of Proteobioactives and the Pentacoxib™ oral therapy.

Cavalier Resources progresses its Crawford Gold Project with key milestones including an $11 million stream finance negotiation with Raptor Capital and the appointment of Colin Bald as General Manager of Operations.

SomnoMed reports a robust Q4 FY25 with 25% revenue growth and a milestone of treating over 1 million patients, while gearing up for significant capacity expansion and clinical advancements.